Free Trial
NASDAQ:ACHL

Achilles Therapeutics (ACHL) Stock Price, News & Analysis

Achilles Therapeutics logo
$1.08 0.00 (0.00%)
(As of 11/29/2024 ET)

About Achilles Therapeutics Stock (NASDAQ:ACHL)

Key Stats

Today's Range
$1.05
$1.08
50-Day Range
$0.95
$1.08
52-Week Range
$0.63
$1.76
Volume
22,605 shs
Average Volume
446,790 shs
Market Capitalization
$44.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Hold

Company Overview

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Achilles Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
48th Percentile Overall Score

ACHL MarketRank™: 

Achilles Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 626th out of 964 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Achilles Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Achilles Therapeutics has received no research coverage in the past 90 days.

  • Read more about Achilles Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Achilles Therapeutics are expected to grow in the coming year, from ($1.70) to ($1.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Achilles Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Achilles Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Achilles Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.57% of the float of Achilles Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Achilles Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Achilles Therapeutics has recently increased by 35.40%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Achilles Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Achilles Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.57% of the float of Achilles Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Achilles Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Achilles Therapeutics has recently increased by 35.40%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Achilles Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Achilles Therapeutics this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Achilles Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Achilles Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.38% of the stock of Achilles Therapeutics is held by insiders.

  • Percentage Held by Institutions

    56.38% of the stock of Achilles Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Achilles Therapeutics' insider trading history.
Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACHL Stock News Headlines

Ever heard of this 8-day bitcoin profit window?
Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.
Achilles Therapeutics reports Q3 EPS (48c) vs. (42c) last year
Achilles Therapeutics Explores Strategic Options Amid Financial Update
See More Headlines

ACHL Stock Analysis - Frequently Asked Questions

Achilles Therapeutics' stock was trading at $0.8890 at the start of the year. Since then, ACHL shares have increased by 20.9% and is now trading at $1.0750.
View the best growth stocks for 2024 here
.

Achilles Therapeutics plc (NASDAQ:ACHL) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.41) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.41).

Achilles Therapeutics (ACHL) raised $176 million in an initial public offering (IPO) on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO.

Top institutional shareholders of Achilles Therapeutics include BML Capital Management LLC (9.98%).

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Block (SQ), Digital Turbine (APPS), Palantir Technologies (PLTR), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/14/2024
Today
11/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACHL
Fax
N/A
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$6.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+272.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-69,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.51 per share

Miscellaneous

Free Float
38,889,000
Market Cap
$44.18 million
Optionable
Not Optionable
Beta
1.35
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ACHL) was last updated on 11/30/2024 by MarketBeat.com Staff
From Our Partners